Pulse Biosciences stock hits all-time high at 58.94 USD
Pulse Biosciences Inc. (PLSE) has reached an all-time high stock price of $58.94, driven by a 272.91% surge over the last year and a 1,600% revenue increase in the past twelve months. Despite concerns of potential overvaluation by InvestingPro, the company reported a slightly wider-than-expected Q3 2026 loss of $0.32 per share on $395,000 in revenue, with Mizuho raising its price target to $65 due to early completion of a key study enrollment.
Form 8K Pulse Biosciences Inc For: 6 November By Investing.com
This article from Investing.com announces the filing of a Form 8K by Pulse Biosciences Inc (PLSE) on November 6th. The brief notice provides the company's stock symbol and a minimal positive price change, indicating a standard regulatory disclosure.
Pulse Biosciences Presents Six-Month Interim Results from the PRECISE-BTN Multicenter Study at the American Thyroid Association Annual Meeting
Pulse Biosciences announced positive six-month interim results from its PRECISE-BTN multicenter study for benign thyroid nodules, presented at the American Thyroid Association Annual Meeting. The study showed that 86% of patients achieved at least 50% nodule volume reduction after a single nonthermal nsPFA treatment, with significant improvements in symptoms and quality of life and no serious adverse events. The nPulse™ Vybrance™ Percutaneous Electrode System offers a nonthermal, ultrasound-guided option that preserves critical structures and provides same-day discharge for patients.
What Pulse Biosciences (PLSE) Said on Its Q3 Earnings Call
Pulse Biosciences (PLSE) reported its Q3 earnings, detailing increased revenue but also a wider net loss. The company completed enrollment ahead of schedule for its nPulse Cardiac Catheter study, with data expected in Q3 2027, and is advancing its surgical and thyroid programs. Pulse Biosciences is preparing for a potential launch in early 2028 and increasing manufacturing capacity while also exploring partnership opportunities.
Neck symptoms fully resolved in 82% of those reporting them; nodules shrank by at least half in 86% of patients at six months.
Pulse Biosciences (Nasdaq: PLSE) announced positive interim six-month results from its PRECISE-BTN study, evaluating its nPulse™ Vybrance™ Percutaneous Electrode System for benign thyroid nodules. The study showed that 86% of patients achieved at least a 50% nodule volume reduction, with a median reduction of 72%. Additionally, 82% of patients with baseline neck symptoms reported full resolution, and no serious adverse events occurred.
Pulse Biosciences Inc (PLSE) Q3 2026 Earnings Call Highlights: NanoPulse AF Study Enrollment ...
Pulse Biosciences (PLSE) announced the early completion of enrollment for its NanoPulse AF pivotal IDE study, finishing three months ahead of schedule with 169 evaluable patients. The company reported a strong cash position of $189 million, providing approximately two years of cash runway, bolstered by over $150 million raised through its ATM program. Despite a GAAP net loss of $23.1 million in Q3 2026, Pulse Biosciences remains confident in its launch readiness, scaling manufacturing, and differentiated nanosecond PFA technology, which CEO Paul LaViolette believes offers superior clinical outcomes and procedural efficiency compared to current microsecond PFA devices.
Pulse Biosciences earnings missed by $0.01, revenue fell short of estimates
Pulse Biosciences (NASDAQ: PLSE) reported third-quarter earnings per share of $-0.32, missing analyst estimates by $0.01. The company's revenue for the quarter was $395K, which also fell short of the consensus estimate of $605K. Despite the earnings miss, Pulse Biosciences' stock has seen significant gains, up 25.14% in the last 3 months and 243.27% in the last 12 months.
Pulse Biosciences Reports Business Updates and Third Quarter 2026 Financial Results
Pulse Biosciences announced business updates and financial results for the third quarter ended September 30, 2026, highlighting the completion of enrollment for its NANOPULSE-AF US IDE pivotal study three months ahead of schedule. The company reported $189 million in cash, cash equivalents, and marketable securities, reflecting a significant strengthening of its balance sheet. Pulse Biosciences is now focusing on launch readiness, additional data readouts, and regulatory submissions for its nPulse Cardiac Catheter System.
Earnings Preview: PLSE to Report Financial Results Post-market on November 05
Pulse Biosciences (PLSE) is expected to announce its financial results after the market closes on November 5. Analysts predict the company will report a quarterly loss of $0.27 per share, an improvement from the $0.35 loss per share reported in the same quarter last year. Revenue is projected to reach $1.99 million, a significant increase from $0.65 million in the prior year's comparable quarter.
Pulse Biosciences stock trades at EUR 48.80 late Thursday
Pulse Biosciences stock traded at EUR 48.80 late Thursday, October 29, 2026, according to Lang & Schwarz, as the company prepares to report its third-quarter 2026 financial results on November 5. The medical technology company, which develops bioelectric medicine applications based on its Nano-Pulse Stimulation technology, will also host a conference call for investors to provide updates on commercial progress and platform development.
(PLSE) Movement Within Algorithmic Entry Frameworks
Pulse Biosciences Inc (NASDAQ: PLSE) is showing a mid-channel oscillation pattern with strong near-term sentiment potentially leading to a long-term positive bias. AI models have generated three trading strategies—Position Trading (LONG), Momentum Breakout (BREAKOUT), and Risk Hedging (SHORT)—tailored to different risk profiles. The analysis highlights an exceptional risk-reward short setup targeting 15.8% downside with minimal risk.
Pulse Biosciences, Inc Estimates – NASDAQ:PLSE
This article provides an overview of Pulse Biosciences, Inc.'s financial data and analyst estimates on TradingView. It highlights key financial statements such as the income statement, balance sheet, and cash flow, along with valuation metrics. Users can compare actual results with average, high, and low estimates and visualize trends over time.
Pulse Biosciences Schedules Third Quarter 2026 Financial Results Conference Call for November 5, 2026
Pulse Biosciences, Inc. (Nasdaq: PLSE) announced it will report its third-quarter 2026 financial results and business updates after market close on Thursday, November 5, 2026. Company management will host a conference call at 1:30 PM PT / 4:30 PM ET to discuss these updates. Investors can access the call via phone or a live and recorded webcast on the Pulse Biosciences Investors website.
Pulse Biosciences Schedules Third Quarter 2026 Financial Results Conference Call for November 5, 2026
Pulse Biosciences, Inc. (Nasdaq: PLSE) announced it will report its third quarter 2026 business updates and financial results on Thursday, November 5, 2026, after market close. The company's management will host a conference call at 1:30 PM PT / 4:30 PM ET to discuss these updates. Investors can join the call via phone or access a live and recorded webcast on the Pulse Biosciences Investors website.
Pulse Biosciences has a November 5 earnings date: Pulse Biosciences stock gains 10.05 percent
Pulse Biosciences (PLSE) saw its stock rise by 10.05% on October 20, 2026, trading at EUR 46.00. The company has an upcoming earnings report on November 5, 2026, after reporting second-quarter 2026 revenue of USD 434,000 and a net loss of USD 24.66 million, missing analyst expectations. Oppenheimer recently raised its price target for Pulse Biosciences to USD 60.00 with an Outperform rating.
Total cash dividends paid of Pulse Biosciences, Inc. – FWB:6L8
This article provides financial information for Pulse Biosciences, Inc. (FWB:6L8) regarding its total cash dividends paid. It indicates that the market is currently closed with no trades. The content is primarily a listing on TradingView, focusing on the financial overview of the company.
Pulse Biosciences, Inc. Balance Sheet – XETR:6L8
Pulse Biosciences, Inc. (XETR:6L8) reported its Q2 2026 financial position. Total assets for Q2 2026 reached 101.19 M EUR, marking a 43.23% increase from Q1 2026. Concurrently, total liabilities rose by 6.05% to 14.07 M EUR in the same quarter.
Oppenheimer lifts target to USD 60.00 for Pulse Biosciences stock
Oppenheimer has increased its price target for Pulse Biosciences (PLSE) stock from $35.00 to $60.00, citing the company's bioelectric medicine business and its upcoming earnings report on November 5, 2026. The stock closed at $44.43 on October 16, 2026, and the new target is 35.63% above this closing price. The article highlights the importance of the upcoming earnings report in the context of the company's negative P/E and $3.2 billion market capitalization.
Oppenheimer lifts target for Pulse Biosciences stock to USD 60.00
Oppenheimer has raised its price target for Pulse Biosciences (PLSE) stock to $60.00, up from $35.00, while maintaining an Outperform rating. Mizuho also increased its target to $55.00. The company's stock was trading at $44.22 on Nasdaq and EUR 39.50 at Lang & Schwarz on October 15, 2026, with its next earnings report expected on November 15, 2026.
Oppenheimer maintains Outperform rating on Pulse Biosciences, $60 price target
Oppenheimer has reiterated its Outperform rating on Pulse Biosciences (PLSE), setting a price target of $60, indicating a potential upside of 14.4% from its previous closing price. This positive outlook is driven by the promising clinical potential of Pulse Biosciences' Nano-Pulse Stimulation (NPS) technology in immuno-oncology and the company's favorable market positioning against competitors. The anticipated results from a pivotal clinical trial in 2027 are expected to further validate the technology's effectiveness and boost investor confidence.
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Pulse Biosciences has granted equity awards to two new employees under Nasdaq Listing Rule 5635(c)(4) as inducement for their employment. The awards consist of options to purchase up to 5,700 shares of common stock, with an exercise price of $49.98 per share and a four-year time-based vesting schedule. These grants were made outside the Company's 2017 Equity Incentive Plan but under the 2017 Inducement Equity Incentive Plan.
Pulse Biosciences (NasdaqCM:PLSE) Stock Price
Pulse Biosciences (PLSE) stock is currently valued at US$53.81, with a fair value of US$54.00, suggesting it is fairly valued. The company recently completed patient enrollment for its pivotal NANOPULSE-AF trial for its nPulse Cardiac Catheter System, a major step towards regulatory approval and commercialization. Analyst consensus targets vary, with some seeing significant upside potential based on the nanosecond pulsed field ablation technology.
Pulse Biosciences stock reaches 164 patient study target
Pulse Biosciences (PLSE) has reached its 164-patient enrollment target in its pivotal atrial fibrillation study for the NANOPULSE-AF IDE, three months ahead of schedule. While analysts show a divided valuation with an average 12-month price target of USD 50.20, investors are awaiting six-month and 12-month safety and effectiveness outcomes, with pivotal data expected at a future medical conference. The stock was trading at USD 50.66 on October 7, 2026, near its 52-week high.
Pulse Biosciences Achieves Enrollment Target in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse Cardiac Catheter System for Atrial Fibrillation Treatment
Pulse Biosciences announced that its NANOPULSE-AF Study has successfully reached its enrollment target of 164 evaluable patients across 15 clinical sites, three months ahead of schedule. The study is evaluating the safety and effectiveness of the nPulse Cardiac Catheter System for treating drug-resistant atrial fibrillation. The rapid enrollment highlights significant investigator interest and the system's efficient procedural workflow.
Pulse Biosciences Achieves Full Enrollment of 164 Patients in NANOPULSE-AF Clinical Trial
Pulse Biosciences announced the full enrollment of 164 evaluable patients in its NANOPULSE-AF IDE pivotal clinical trial. This multi-site study aims to assess the nPulse Cardiac Catheter System for treating drug-resistant, symptomatic, paroxysmal atrial fibrillation, with primary endpoints to be evaluated at 6 and 12 months post-ablation. The achievement marks a significant milestone for the company as it progresses towards potential treatment for atrial fibrillation.
Pulse Biosciences hits 164-patient enrollment target in NANOPULSE-AF pivotal IDE study
Pulse Biosciences has successfully reached its enrollment target of 164 evaluable patients for the NANOPULSE-AF pivotal IDE study, three months ahead of schedule. This study, evaluating the nPulse Cardiac Catheter System in patients with drug-resistant paroxysmal atrial fibrillation, began treating patients in April 2026, with primary endpoints to be assessed at 6 and 12 months post-ablation. The company plans to provide further updates as patients complete their follow-up.
Pulse Biosciences completes enrollment in cardiac ablation study
Pulse Biosciences Inc. (NASDAQ:PLSE) has announced the completion of enrollment in its NANOPULSE-AF Study, reaching 164 evaluable patients three months ahead of schedule. This pivotal clinical investigation evaluates the safety and effectiveness of the nPulse Cardiac Catheter System for treating drug-resistant paroxysmal atrial fibrillation. The company's nPulse technology uses a non-thermal approach with nanosecond electrical pulses to clear cells while sparing adjacent non-cellular tissue.
Pulse Biosciences Achieves Enrollment Target in NANOPULSE-AF IDE
Pulse Biosciences has successfully reached its enrollment target of 164 evaluable patients for its NANOPULSE-AF IDE pivotal clinical study, evaluating the nPulse™ Cardiac Catheter System for atrial fibrillation treatment. This achievement occurred three months ahead of schedule, reflecting significant investigator interest and efficient workflow at the 15 participating clinical sites. The company plans to present pivotal data at a future medical conference as patient follow-up concludes.
Pulse Biosciences completes enrollment in cardiac ablation study By Investing.com
Pulse Biosciences (NASDAQ:PLSE) has successfully completed enrollment for its NANOPULSE-AF Study, a pivotal clinical investigation into the safety and effectiveness of its nPulse Cardiac Catheter System for treating drug-resistant paroxysmal atrial fibrillation. The company reached its target of 164 evaluable patients three months ahead of schedule. Primary endpoints will be assessed at six and 12 months post-ablation, with future data presentations expected at medical conferences.
Pulse Biosciences hits enrollment target in atrial fibrillation study
Pulse Biosciences has successfully reached its enrollment target of 164 evaluable patients for its NANOPULSE-AF Study, evaluating the nPulse Cardiac Catheter System for treating atrial fibrillation. The study completed enrollment three months ahead of schedule across 15 clinical sites. The nPulse system utilizes Nanosecond Pulsed Field Ablation technology, and primary endpoints will be assessed at 6 and 12 months post-ablation.
(PLSE) Movement Within Algorithmic Entry Frameworks
This article analyzes Pulse Biosciences Inc (NASDAQ: PLSE) using algorithmic entry frameworks. It highlights a weak near and mid-term sentiment but a strong long-term outlook, identifying an exceptional short setup with a 61.3:1 risk-reward ratio. The analysis provides distinct trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored for different risk profiles, along with multi-timeframe signal analysis.
Canaccord raises target for Pulse Biosciences stock from USD 43.00 to USD 58.00
Canaccord has increased its price target for Pulse Biosciences (PLSE) from USD 43.00 to USD 58.00, maintaining a Buy rating, following a virtual non-deal roadshow. This updated target surpasses the average 12-month target of USD 50.20, reflecting a valuation and comparison-group decision rather than a new earnings forecast. The company recently completed enrollment for its PRECISE-BTN study, yet faces financial pressure with Q2 revenue of USD 0.43 million against an expected USD 0.53 million and a higher-than-expected loss per share.
Canaccord raises Pulse Biosciences stock price target on tech potential By Investing.com
Canaccord has increased its price target for Pulse Biosciences (NASDAQ:PLSE) to $58 from $43, while maintaining a Buy rating. The firm's decision follows a non-deal roadshow with Pulse Biosciences' CEO and CFO, and highlights the company's nanosecond pulse field ablation platform, clinical evidence, and commercial strategy for its atrial fibrillation business. Pulse Biosciences stock has seen significant growth, rising 87.5% since Canaccord initiated coverage in June 2026, and a remarkable 268% year-to-date.
Pulse Biosciences stock gets a higher fair value estimate
Pulse Biosciences (PLSE) has received a higher fair value estimate of USD 54.00 per share, up from USD 45.25, following positive clinical data and upcoming milestones. Despite a Q2 2026 revenue of USD 434,000, falling short of expectations, the company maintains a strong cash position of USD 101.6 million. Clinical trials for its nPulse Vybrance Percutaneous Electrode System are progressing, with the next earnings report due on November 16, 2026.
BTIG sets a USD 70 target for Pulse Biosciences stock
BTIG has initiated coverage on Pulse Biosciences (PLSE) with a Buy rating and a $70 price target, citing the company's nanosecond pulsed field ablation technology and early clinical evidence. This target is above the broader consensus of $50.20. Pulse Biosciences recently achieved a clinical milestone by enrolling its 100th patient in the PRECISE-BTN study, although revenue remains in the early stages, with the company reporting $434,000 in the last quarter.
Pulse Biosciences stock faces Oppenheimer meeting after 3.87 percent fall
Pulse Biosciences stock (PLSE) fell 3.87% to USD 47.90 on October 2, 2026, ahead of a key management meeting with Oppenheimer in San Francisco on October 7-8, 2026. The company reported Q2 2026 revenue of USD 434,000 and an adjusted loss of USD 0.36 per share, missing consensus estimates. Analysts maintain a "Moderate Buy" rating with an average price target of USD 50.20, emphasizing the need for regulatory progress and market adoption of its Nano-Pulse Stimulation technology.
Pulse Biosciences (PLSE) Stock Analysis Report | Ratings, Financials & Performance
This report provides a comprehensive analysis of Pulse Biosciences (PLSE), a bioelectric medicine company, covering its stock performance, financial health, and future growth potential. It details the company's patented Nano-Pulse Stimulation technology and includes Benzinga Edge Rankings, peer comparisons, analyst ratings, and financial statements for investors. The report aims to help identify the stock's strengths and weaknesses for potential buyers and sellers.
BTIG initiates Pulse Biosciences stock coverage with buy rating
BTIG has initiated coverage on Pulse Biosciences (NASDAQ:PLSE) with a "Buy" rating and a $70.00 price target, aligning with a "Strong Buy" analyst consensus. The company's Nanosecond Pulsed Field Ablation technology has shown promising clinical results, with a U.S. pivotal study underway and potential FDA approval by late 2027 or early 2028. Despite a recent wider-than-expected loss and revenue miss, analysts remain optimistic due to technological advancements and market potential.
Pulse Biosciences stock reports 100 patient trial milestone
Pulse Biosciences has reached a 100-patient milestone in its PRECISE-BTN thyroid nodule study, doubling the initial enrollment goal. The company holds $101.6 million in cash and has secured additional financing capacity, positioning it for continued clinical and commercial development. Despite a recent daily decline, the stock remains in the upper part of its annual range, with investors looking forward to preliminary trial data and regulatory progress for its nPulse Vybrance system.
Is Pulse Biosciences (PLSE) Fully Valued As Its Thyroid Trial Reaches 100 Patients?
Pulse Biosciences (PLSE) has completed enrollment for 100 patients in its PRECISE-BTN thyroid nodule study, with the first participant having reached a 12-month follow-up. Despite recent stock fluctuations, PLSE has seen a significant year-to-date return of 298.1%. The company, valued at approximately US$3.8 billion, is considered 18% overvalued against a fair value of $45.25, with its future growth heavily reliant on pivotal trial outcomes and scaling up from its current US$1.2 million revenue base.
BTIG initiates coverage of Pulse Biosciences with Buy rating, $70 price target
BTIG has initiated coverage on Pulse Biosciences (PLSE) with a Buy rating and a $70 price target, suggesting a 32.9% upside from its Sep 22 close. The positive outlook is attributed to the company's innovative Nanosecond Pulsed Field Ablation (nsPFA) technology, which has shown strong clinical results, and its strategic partnership model for U.S. commercialization. This approach is expected to enhance market entry and mitigate financial risks.
BTIG initiates Pulse Biosciences stock coverage with buy rating
BTIG has initiated coverage on Pulse Biosciences (NASDAQ:PLSE) with a buy rating and a $70.00 price target, aligning with a "Strong Buy" consensus despite the stock's 284% year-to-date return. The company's Nanosecond Pulsed Field Ablation technology for cardiac ablation shows promising clinical results, with a potential FDA approval by late 2027 or early 2028. While analysts project significant sales growth, InvestingPro's Fair Value suggests the stock may be overvalued at current levels.
BTIG Initiates Pulse Biosciences at Buy With $70 Price Target
BTIG has initiated coverage of Pulse Biosciences (PLSE) with a "Buy" rating and a price target of $70. This new price target is higher than the average analyst target of $54 for the company. The article, however, is a premium piece, requiring a subscription to read the full details.
Pulse Biosciences Completes Enrollment in the PRECISE-BTN Clinical Study Evaluating the nPulse™ Vybrance™ Percutaneous Electrode System for Symptomatic Benign Thyroid Nodules
Pulse Biosciences has announced the completion of enrollment in its PRECISE-BTN clinical study, evaluating the nPulse™ Vybrance™ Percutaneous Electrode System for symptomatic benign thyroid nodules. The study successfully enrolled 100 patients across three U.S. clinical sites, doubling its original patient count, and the first patient has already completed their 12-month follow-up. The company plans to present preliminary data soon and full data upon completion of all 12-month follow-ups.
Form 8K Pulse Biosciences Inc For: 15 September By Investing.com
This article is a Form 8K filing for Pulse Biosciences Inc (PLSE) dated September 15. The company's stock symbol is PLSE, and its stock price showed a 3.48% increase. The article mentions that the Form 8K was published on September 15, 2026, at 04:52 p.m.
Pulse Biosciences Completes Enrollment in the PRECISE-BTN Clinical Study Evaluating the nPulse Vybrance Percutaneous Electrode System for Symptomatic Benign Thyroid Nodules
Pulse Biosciences has announced the completion of enrollment for its PRECISE-BTN clinical study, which evaluates the nPulse Vybrance Percutaneous Electrode System for treating symptomatic benign thyroid nodules. The study successfully enrolled 100 patients across three U.S. sites, doubling its original target. The company plans to present preliminary data from the study at an upcoming medical conference, with full data expected after all patients complete their 12-month follow-up.
Pulse Biosciences enters $85 million equity distribution agreement with Mizuho
Pulse Biosciences (NASDAQ:PLSE) has entered into an equity distribution agreement with Mizuho Securities USA LLC, allowing it to sell up to $85 million of its common stock. This new agreement follows a previous $75 million agreement with Mizuho, under which the company had already sold approximately $68.8 million in shares. The company also terminated an earlier agreement with TD Securities.
Form 8K Pulse Biosciences Inc For: 15 September By Investing.com
This article reports on Pulse Biosciences Inc.'s Form 8K filing for September 15. The brief announcement provides no specific details from the filing but indicates it is a standard regulatory disclosure.
Pulse Biosciences Finalizes Enrollment for PRECISE-BTN Trial Evaluating nPulse Vybrance System
Pulse Biosciences (NASDAQ:PLSE) has successfully completed patient enrollment for its PRECISE-BTN clinical trial, which evaluates the nPulse Vybrance Percutaneous Electrode System for treating symptomatic benign thyroid nodules. The study expanded from 50 to 100 patients, with enrollment occurring at three U.S. clinical sites. The first patient has also completed their 12-month follow-up, and the trial will assess safety, nodule volume reduction, symptom relief, hormone normalization, and quality of life improvements.
Freedom Capital initiates Pulse Biosciences stock with buy rating By Investing.com
Freedom Capital has initiated coverage on Pulse Biosciences (NASDAQ: PLSE) with a Buy rating and a $73.00 price target, suggesting a 50% upside from its current trading price of $48.79. The firm highlighted the potential of Pulse Biosciences' nsPFA technology to disrupt the atrial fibrillation ablation market and noted the company's strong financial position. This initiation follows other positive analyst coverage and advancements in the company's clinical trials, despite a recent wider-than-expected loss.